Epirus Biopharmaceuticals (EPRS) Posts Quarterly Results
Epirus Biopharmaceuticals (NASDAQ:EPRS) released its earnings data on Wednesday. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.32, AR Network reports.
Epirus Biopharmaceuticals (NASDAQ:EPRS) opened at 8.84 on Wednesday. Epirus Biopharmaceuticals has a 52 week low of $7.44 and a 52 week high of $82.80. The stock’s 50-day moving average is $9.53 and its 200-day moving average is $11.61. The company’s market cap is $25.8 million.
EPIRUS Biopharmaceuticals Inc, formerly Zalicus Inc, is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.